Project Grant R01AI187131
Award Date
6/12/25
Completion Date
5/31/30
Dollars Obligated
$782K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Stony Brook, NY 11794, USA
Similar Awards
This $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to discover and develop new, more potent antifungal therapies for treating invasive fungal infections such as cryptococcosis, candidiasis, and aspergillosis. The funding will support the continued screening of chemical libraries to identify lead compounds that selectively inhibit the fungal ceramide synthase 1...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to study the role of the host sphingosine kinase 1 (SK1) pathway in controlling infection by the fungus Cryptococcus neoformans during immunodeficiency. The $749,594 award, effective from February 1, 2025 to January 31, 2030, will support research to: 1) Determine the immune mechanism by which the SK1-S1P pathway regulates...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $170,000.00 in funding to Prokaryotics Incorporated for a 2-year period from February 1, 2025 to January 31, 2027. The funding supports research to develop novel antifungal therapeutics that target the glycosylphosphatidylinositol (GPI) biosynthesis pathway in fungi. The key objectives are to conduct structural...
This $642,775 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund research to accelerate the discovery of novel antifungal peptides using one-bead one-compound (OBOC) combinatorial technology. The University of California, Davis will conduct high-throughput screening of chemically synthesized peptide libraries to identify membrane-active antifungal peptides that can...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, has awarded a $300,156 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Intact Genomics Inc., a minority-owned small business. The funding will support research to identify new antifungal compounds with novel mechanisms of action from filamentous fungi. The key objectives are to demonstrate the use of Aspergillus nidulans as a...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $2,917,725.00 to The Regents of the University of Colorado for the development of novel antifungal agents to treat coccidioidomycosis, a serious fungal infection endemic to the Southwestern U.S. The key objectives are to perform structure-activity relationship studies on a lead natural product candidate, investigate its mechanism of action, and...
This $265,650 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund research to elucidate the evolutionary dynamics of the gut-colonizing fungus Candida glabrata. The award will enable the use of barcode-enabled lineage tracking techniques to study how antifungal drug treatment and immune dysfunction influence the adaptation and evolution of C. glabrata in the host...
The University of Southern California (USC) received a $623,986 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The funding supports a research project to study the genetic and molecular mechanisms that enable fungi, specifically the opportunistic pathogen Saccharomyces cerevisiae, to persist and cause infections in mammalian hosts. Key objectives include: Identifying causal...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to support the preclinical development of occidiofungin, a novel antifungal compound, for the treatment of oral and dermal candidiasis. The key objectives are to establish an effective formulation, conduct toxicological and stability studies, and prepare an Investigational New Drug (IND) application...
This $857,215 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate how the fungal pathogen Candida albicans adapts and causes disease in different host environments. The research aims to decipher how the fungal protein acetylation regulator GCN5 mediates niche-specific virulence of C. albicans in mouse models of oropharyngeal and invasive candidiasis. By...